{"id":4097,"date":"2026-06-09T08:57:03","date_gmt":"2026-06-09T15:57:03","guid":{"rendered":"https:\/\/xpharma.com.cn\/?p=4097"},"modified":"2026-06-09T08:57:05","modified_gmt":"2026-06-09T15:57:05","slug":"teva-%ef%bc%9aajovyfremanezumab-vfrmapproved-for-marketing-in-china","status":"publish","type":"post","link":"https:\/\/xpharma.com.cn\/index.php\/news\/teva-%ef%bc%9aajovyfremanezumab-vfrmapproved-for-marketing-in-china\/","title":{"rendered":"Teva\u00a0\uff1aAJOVY\u00aeFremanezumab-vfrmapproved for marketing in China."},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>On June 8, the NMPA official website showed that Teva Pharmaceuticals&#8217; Fremanezumab Injection has been approved for marketing in China.<\/strong>&nbsp;Based on public information and clinical trial progress, the Insight database speculates that the approved indication is for the preventive treatment of migraine.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Fremanezumab (AJOVY, formerly known as Renmabizumab) is an innovative migraine treatment developed by Teva Pharmaceuticals.<\/strong>&nbsp;It selectively binds to the calcitonin gene-related peptide (CGRP) ligand and blocks the binding of both CGRP subtypes (\u03b1- and \u03b2-CGRP) to their receptors.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Fremanezumab offers flexible subcutaneous dosing regimens: once quarterly (675 mg) or once monthly (225 mg).<\/strong>&nbsp;It was first approved for adult indications by the U.S. FDA in 2018. In 2025, the FDA expanded the approval, making it the first anti-CGRP preventive treatment for episodic migraine in children and adolescents. The drug is currently approved and marketed in multiple countries and regions, including the United States, the European Union, Japan, and South Korea.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>In China, Fremanezumab was first approved by the Guangdong Provincial Drug Administration in 2023 under the &#8220;Hong Kong-Macao Drug and Medical Device Connect&#8221; policy, becoming available in the Guangdong-Hong Kong-Macao Greater Bay Area.<\/strong>&nbsp;In January 2025, the marketing application for Fremanezumab was accepted by the CDE, and it has now received official approval as of today.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Buy <strong>AJOVY\u00ae<\/strong><strong>\uff08<\/strong><strong>Fremanezumab-vfrm<\/strong><strong>\uff09<\/strong><strong>&nbsp;<\/strong>online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>On June 8, the NMPA official website showed that Teva Pharmaceuticals&#8217; Fremanezumab Injection has been approved for marketing in China.&nbsp;Based on public information and clinical trial progress, the Insight database speculates that the approved indication is for the preventive treatment of migraine. Fremanezumab (AJOVY, formerly known as Renmabizumab) is an innovative migraine treatment developed by [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":2771,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16],"tags":[],"class_list":["post-4097","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"blocksy_meta":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Teva\u00a0\uff1aAJOVY\u00aeFremanezumab-vfrmapproved for marketing in China. - Xpharma China<\/title>\n<meta name=\"description\" content=\"Teva\u00a0\uff1aAJOVY\u00aeFremanezumab-vfrmapproved for marketing in China. - Xpharma China\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/xpharma.com.cn\/index.php\/news\/teva-\uff1aajovyfremanezumab-vfrmapproved-for-marketing-in-china\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Teva\u00a0\uff1aAJOVY\u00aeFremanezumab-vfrmapproved for marketing in China. - Xpharma China\" \/>\n<meta property=\"og:description\" content=\"Teva\u00a0\uff1aAJOVY\u00aeFremanezumab-vfrmapproved for marketing in China. - Xpharma China\" \/>\n<meta property=\"og:url\" content=\"https:\/\/xpharma.com.cn\/index.php\/news\/teva-\uff1aajovyfremanezumab-vfrmapproved-for-marketing-in-china\/\" \/>\n<meta property=\"og:site_name\" content=\"Xpharma China\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/61590027634719\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-09T15:57:03+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-09T15:57:05+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/05\/teva.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"344\" \/>\n\t<meta property=\"og:image:height\" content=\"146\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"xpharmanews\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@Xpharma007\" \/>\n<meta name=\"twitter:site\" content=\"@Xpharma007\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"xpharmanews\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/teva-%ef%bc%9aajovyfremanezumab-vfrmapproved-for-marketing-in-china\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/teva-%ef%bc%9aajovyfremanezumab-vfrmapproved-for-marketing-in-china\\\/\"},\"author\":{\"name\":\"xpharmanews\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#\\\/schema\\\/person\\\/c292b26c0a3311036ce0f5ab28a1ea05\"},\"headline\":\"Teva\u00a0\uff1aAJOVY\u00aeFremanezumab-vfrmapproved for marketing in China.\",\"datePublished\":\"2026-06-09T15:57:03+00:00\",\"dateModified\":\"2026-06-09T15:57:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/teva-%ef%bc%9aajovyfremanezumab-vfrmapproved-for-marketing-in-china\\\/\"},\"wordCount\":251,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/teva-%ef%bc%9aajovyfremanezumab-vfrmapproved-for-marketing-in-china\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/teva.jpg\",\"articleSection\":[\"Approved News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/teva-%ef%bc%9aajovyfremanezumab-vfrmapproved-for-marketing-in-china\\\/#respond\"]}]},{\"@type\":[\"WebPage\",\"MedicalWebPage\"],\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/teva-%ef%bc%9aajovyfremanezumab-vfrmapproved-for-marketing-in-china\\\/\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/teva-%ef%bc%9aajovyfremanezumab-vfrmapproved-for-marketing-in-china\\\/\",\"name\":\"Teva\u00a0\uff1aAJOVY\u00aeFremanezumab-vfrmapproved for marketing in China. - Xpharma China\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/teva-%ef%bc%9aajovyfremanezumab-vfrmapproved-for-marketing-in-china\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/teva-%ef%bc%9aajovyfremanezumab-vfrmapproved-for-marketing-in-china\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/teva.jpg\",\"datePublished\":\"2026-06-09T15:57:03+00:00\",\"dateModified\":\"2026-06-09T15:57:05+00:00\",\"description\":\"Teva\u00a0\uff1aAJOVY\u00aeFremanezumab-vfrmapproved for marketing in China. - Xpharma China\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/teva-%ef%bc%9aajovyfremanezumab-vfrmapproved-for-marketing-in-china\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/teva-%ef%bc%9aajovyfremanezumab-vfrmapproved-for-marketing-in-china\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/teva-%ef%bc%9aajovyfremanezumab-vfrmapproved-for-marketing-in-china\\\/#primaryimage\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/teva.jpg\",\"contentUrl\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/teva.jpg\",\"width\":344,\"height\":146},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/news\\\/teva-%ef%bc%9aajovyfremanezumab-vfrmapproved-for-marketing-in-china\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"\u9996\u9875\",\"item\":\"https:\\\/\\\/xpharma.com.cn\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Teva\u00a0\uff1aAJOVY\u00aeFremanezumab-vfrmapproved for marketing in China.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#website\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/\",\"name\":\"Xpharma China - International Pharmaceutical wholesaler and retailer\",\"description\":\"Xpharma China\",\"publisher\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/xpharma.com.cn\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#organization\",\"name\":\"Xpharma China\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/logo.gif\",\"contentUrl\":\"https:\\\/\\\/xpharma.com.cn\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/logo.gif\",\"width\":679,\"height\":166,\"caption\":\"Xpharma China\"},\"image\":{\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/61590027634719\\\/\",\"https:\\\/\\\/x.com\\\/Xpharma007\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/xpharma.com.cn\\\/#\\\/schema\\\/person\\\/c292b26c0a3311036ce0f5ab28a1ea05\",\"name\":\"xpharmanews\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g\",\"caption\":\"xpharmanews\"},\"url\":\"https:\\\/\\\/xpharma.com.cn\\\/index.php\\\/author\\\/xpharmanews\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Teva\u00a0\uff1aAJOVY\u00aeFremanezumab-vfrmapproved for marketing in China. - Xpharma China","description":"Teva\u00a0\uff1aAJOVY\u00aeFremanezumab-vfrmapproved for marketing in China. - Xpharma China","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/xpharma.com.cn\/index.php\/news\/teva-\uff1aajovyfremanezumab-vfrmapproved-for-marketing-in-china\/","og_locale":"en_US","og_type":"article","og_title":"Teva\u00a0\uff1aAJOVY\u00aeFremanezumab-vfrmapproved for marketing in China. - Xpharma China","og_description":"Teva\u00a0\uff1aAJOVY\u00aeFremanezumab-vfrmapproved for marketing in China. - Xpharma China","og_url":"https:\/\/xpharma.com.cn\/index.php\/news\/teva-\uff1aajovyfremanezumab-vfrmapproved-for-marketing-in-china\/","og_site_name":"Xpharma China","article_publisher":"https:\/\/www.facebook.com\/61590027634719\/","article_published_time":"2026-06-09T15:57:03+00:00","article_modified_time":"2026-06-09T15:57:05+00:00","og_image":[{"width":344,"height":146,"url":"http:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/05\/teva.jpg","type":"image\/jpeg"}],"author":"xpharmanews","twitter_card":"summary_large_image","twitter_creator":"@Xpharma007","twitter_site":"@Xpharma007","twitter_misc":{"Written by":"xpharmanews","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/xpharma.com.cn\/index.php\/news\/teva-%ef%bc%9aajovyfremanezumab-vfrmapproved-for-marketing-in-china\/#article","isPartOf":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/teva-%ef%bc%9aajovyfremanezumab-vfrmapproved-for-marketing-in-china\/"},"author":{"name":"xpharmanews","@id":"https:\/\/xpharma.com.cn\/#\/schema\/person\/c292b26c0a3311036ce0f5ab28a1ea05"},"headline":"Teva\u00a0\uff1aAJOVY\u00aeFremanezumab-vfrmapproved for marketing in China.","datePublished":"2026-06-09T15:57:03+00:00","dateModified":"2026-06-09T15:57:05+00:00","mainEntityOfPage":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/teva-%ef%bc%9aajovyfremanezumab-vfrmapproved-for-marketing-in-china\/"},"wordCount":251,"commentCount":0,"publisher":{"@id":"https:\/\/xpharma.com.cn\/#organization"},"image":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/teva-%ef%bc%9aajovyfremanezumab-vfrmapproved-for-marketing-in-china\/#primaryimage"},"thumbnailUrl":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/05\/teva.jpg","articleSection":["Approved News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/xpharma.com.cn\/index.php\/news\/teva-%ef%bc%9aajovyfremanezumab-vfrmapproved-for-marketing-in-china\/#respond"]}]},{"@type":["WebPage","MedicalWebPage"],"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/teva-%ef%bc%9aajovyfremanezumab-vfrmapproved-for-marketing-in-china\/","url":"https:\/\/xpharma.com.cn\/index.php\/news\/teva-%ef%bc%9aajovyfremanezumab-vfrmapproved-for-marketing-in-china\/","name":"Teva\u00a0\uff1aAJOVY\u00aeFremanezumab-vfrmapproved for marketing in China. - Xpharma China","isPartOf":{"@id":"https:\/\/xpharma.com.cn\/#website"},"primaryImageOfPage":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/teva-%ef%bc%9aajovyfremanezumab-vfrmapproved-for-marketing-in-china\/#primaryimage"},"image":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/teva-%ef%bc%9aajovyfremanezumab-vfrmapproved-for-marketing-in-china\/#primaryimage"},"thumbnailUrl":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/05\/teva.jpg","datePublished":"2026-06-09T15:57:03+00:00","dateModified":"2026-06-09T15:57:05+00:00","description":"Teva\u00a0\uff1aAJOVY\u00aeFremanezumab-vfrmapproved for marketing in China. - Xpharma China","breadcrumb":{"@id":"https:\/\/xpharma.com.cn\/index.php\/news\/teva-%ef%bc%9aajovyfremanezumab-vfrmapproved-for-marketing-in-china\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/xpharma.com.cn\/index.php\/news\/teva-%ef%bc%9aajovyfremanezumab-vfrmapproved-for-marketing-in-china\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/xpharma.com.cn\/index.php\/news\/teva-%ef%bc%9aajovyfremanezumab-vfrmapproved-for-marketing-in-china\/#primaryimage","url":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/05\/teva.jpg","contentUrl":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/05\/teva.jpg","width":344,"height":146},{"@type":"BreadcrumbList","@id":"https:\/\/xpharma.com.cn\/index.php\/news\/teva-%ef%bc%9aajovyfremanezumab-vfrmapproved-for-marketing-in-china\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"\u9996\u9875","item":"https:\/\/xpharma.com.cn\/"},{"@type":"ListItem","position":2,"name":"Teva\u00a0\uff1aAJOVY\u00aeFremanezumab-vfrmapproved for marketing in China."}]},{"@type":"WebSite","@id":"https:\/\/xpharma.com.cn\/#website","url":"https:\/\/xpharma.com.cn\/","name":"Xpharma China - International Pharmaceutical wholesaler and retailer","description":"Xpharma China","publisher":{"@id":"https:\/\/xpharma.com.cn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/xpharma.com.cn\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/xpharma.com.cn\/#organization","name":"Xpharma China","url":"https:\/\/xpharma.com.cn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/xpharma.com.cn\/#\/schema\/logo\/image\/","url":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/04\/logo.gif","contentUrl":"https:\/\/xpharma.com.cn\/wp-content\/uploads\/2026\/04\/logo.gif","width":679,"height":166,"caption":"Xpharma China"},"image":{"@id":"https:\/\/xpharma.com.cn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/61590027634719\/","https:\/\/x.com\/Xpharma007"]},{"@type":"Person","@id":"https:\/\/xpharma.com.cn\/#\/schema\/person\/c292b26c0a3311036ce0f5ab28a1ea05","name":"xpharmanews","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5441929ebdec5e836942790743ce7c64c33152cf17fba039e0d79b52418f025f?s=96&d=mm&r=g","caption":"xpharmanews"},"url":"https:\/\/xpharma.com.cn\/index.php\/author\/xpharmanews\/"}]}},"_links":{"self":[{"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/posts\/4097","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/comments?post=4097"}],"version-history":[{"count":1,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/posts\/4097\/revisions"}],"predecessor-version":[{"id":4098,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/posts\/4097\/revisions\/4098"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/media\/2771"}],"wp:attachment":[{"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/media?parent=4097"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/categories?post=4097"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/xpharma.com.cn\/index.php\/wp-json\/wp\/v2\/tags?post=4097"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}